HIGHLIGHTS
- What: The pathology of TBI is complex, involving many biological processes.
- Who: Dezhu Gao and collaborators from the Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China have published the article: FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury, in the Journal: (JOURNAL)
- How: But one research result showed that rats pretreated with rapamycin (2 mg/kg i.p.) 1 h before TBI could dramatically elevate the concentrations of TNF-α IL-1β and IL-6 .
- Future: More research is needed to determine the optimal timing . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.